Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives $81.67 Consensus Price Target from Brokerages

Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) have earned an average rating of “Moderate Buy” from the eleven research firms that are covering the company, Marketbeat Ratings reports. Four analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $81.6667.

ARWR has been the topic of several analyst reports. Morgan Stanley increased their price objective on shares of Arrowhead Pharmaceuticals from $48.00 to $81.00 and gave the company an “equal weight” rating in a report on Wednesday, January 7th. Chardan Capital increased their price target on Arrowhead Pharmaceuticals from $60.00 to $80.00 and gave the company a “buy” rating in a research note on Wednesday, January 7th. Weiss Ratings raised Arrowhead Pharmaceuticals from a “sell (d-)” rating to a “hold (c-)” rating in a research note on Friday, February 6th. The Goldman Sachs Group upped their price objective on Arrowhead Pharmaceuticals from $50.00 to $85.00 and gave the company a “neutral” rating in a report on Wednesday, January 7th. Finally, Piper Sandler reissued an “overweight” rating and issued a $110.00 target price (up previously from $100.00) on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, January 13th.

Insiders Place Their Bets

In other news, CEO Christopher Richard Anzalone sold 13,187 shares of the business’s stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $66.10, for a total value of $871,660.70. Following the completion of the transaction, the chief executive officer owned 3,792,739 shares of the company’s stock, valued at $250,700,047.90. The trade was a 0.35% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Mauro Ferrari sold 7,530 shares of the company’s stock in a transaction on Friday, December 26th. The shares were sold at an average price of $70.00, for a total transaction of $527,100.00. Following the completion of the sale, the director owned 69,053 shares of the company’s stock, valued at approximately $4,833,710. This represents a 9.83% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 510,836 shares of company stock worth $33,603,060 over the last ninety days. Company insiders own 3.60% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Tsfg LLC acquired a new stake in shares of Arrowhead Pharmaceuticals during the fourth quarter worth about $25,000. First Horizon Corp bought a new stake in Arrowhead Pharmaceuticals during the 4th quarter worth approximately $32,000. WPG Advisers LLC raised its holdings in Arrowhead Pharmaceuticals by 384.8% during the 4th quarter. WPG Advisers LLC now owns 543 shares of the biotechnology company’s stock worth $36,000 after buying an additional 431 shares during the period. Hantz Financial Services Inc. boosted its holdings in shares of Arrowhead Pharmaceuticals by 177.1% in the fourth quarter. Hantz Financial Services Inc. now owns 737 shares of the biotechnology company’s stock valued at $49,000 after buying an additional 471 shares during the period. Finally, Elyxium Wealth LLC acquired a new position in shares of Arrowhead Pharmaceuticals in the fourth quarter valued at approximately $54,000. 62.61% of the stock is owned by institutional investors and hedge funds.

Arrowhead Pharmaceuticals Trading Down 0.2%

Shares of ARWR opened at $63.69 on Friday. The stock’s fifty day simple moving average is $66.83 and its 200-day simple moving average is $46.15. The firm has a market capitalization of $8.92 billion, a PE ratio of 41.63 and a beta of 1.21. Arrowhead Pharmaceuticals has a 12-month low of $9.57 and a 12-month high of $76.76. The company has a quick ratio of 3.38, a current ratio of 3.38 and a debt-to-equity ratio of 0.29.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its quarterly earnings data on Thursday, February 5th. The biotechnology company reported $0.22 earnings per share for the quarter, missing the consensus estimate of $0.60 by ($0.38). The firm had revenue of $264.03 million for the quarter, compared to the consensus estimate of $225.66 million. Arrowhead Pharmaceuticals had a return on equity of 35.64% and a net margin of 18.54%.The business’s revenue for the quarter was up 10461.3% compared to the same quarter last year. During the same period in the prior year, the firm posted ($1.39) earnings per share. As a group, research analysts predict that Arrowhead Pharmaceuticals will post -2.42 earnings per share for the current year.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.